Uchiyama Holdings Co., Ltd. (6059) AI Stock Analysis

• Market Cap: ¥6.59B
• Dividend Yield: 2.93%
• Average Volume (3M): 15.13K
• Price to Earnings (P/E): 3.0
• Beta (1Y): 0.38
• Revenue Growth: 0.92%
• EPS Growth: 1344.43%
• Country: JP
• Employees: 2,269
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 9.86
• Shares Outstanding: 21,618,800
• 10 Day Avg. Volume: 20,580
• 30 Day Avg. Volume: 15,133
• PEG Ratio: <0.01
• Price to Book (P/B): 0.42
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -7.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥338.00
• Price Target Upside: -0.88% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: ¥338.00 ▼(-0.88% Downside)

Uchiyama Holdings' overall score is driven by its attractive valuation and positive technical indicators. While financial performance shows some strengths in profitability and reduced leverage, concerns over cash flow sustainability and cost management are notable. The absence of earnings call data and corporate events limits additional insights.

Uchiyama Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Uchiyama Holdings Co., Ltd. (6059) is a diversified company based in Japan, primarily engaged in the manufacturing and distribution of advanced materials and chemical products. The company operates in various sectors, including healthcare, electronics, and industrial materials, offering a range of core products such as pharmaceuticals, specialty chemicals, and advanced polymer materials. Uchiyama Holdings is committed to innovation and sustainability, providing solutions that meet the evolving needs of its customers across multiple industries.

How the Company Makes Money

Uchiyama Holdings generates revenue through multiple streams, prominently through the sale of its pharmaceutical products, specialty chemicals, and advanced materials. The company's pharmaceutical division contributes significantly to its earnings by developing and marketing generic and branded medications. Additionally, the specialty chemicals sector provides high-performance materials used in various applications, including electronics and automotive industries. Strategic partnerships with other manufacturers and research institutions enhance its product offerings and market reach. Furthermore, Uchiyama Holdings invests in research and development to innovate and expand its product lines, which helps in maintaining a competitive edge and driving revenue growth.

Uchiyama Holdings Co., Ltd. Financial Statement Overview

Summary

Uchiyama Holdings shows moderate growth with revenue increase and improved net profit margin. However, declining gross margins and cash flow constraints are concerns. The company has reduced leverage, enhancing financial stability, but maintaining cash flow and managing costs will be critical for future growth.

Income Statement

Uchiyama Holdings shows moderate growth with a revenue increase from 2024 to 2025, yet profitability metrics such as Gross Profit Margin and Net Profit Margin are under pressure. The Gross Profit Margin decreased from 7.29% in 2024 to 6.16% in 2025, indicating cost pressures. The Net Profit Margin, however, improved significantly to 7.05% in 2025 from 0.74% in 2024, mainly due to increased net income. EBIT and EBITDA margins reflect a similar trend of recovery but remain areas of concern compared to previous years.

Balance Sheet

The balance sheet of Uchiyama Holdings reflects a stable equity position with Stockholders' Equity increasing over the years. The Debt-to-Equity Ratio decreased to 0.89 in 2025 from 1.09 in 2024, indicating reduced leverage. The Return on Equity (ROE) improved significantly to 14.40% in 2025, reflecting enhanced profitability. The Equity Ratio stands at 45.86%, showing a robust capital structure, though moderate debt levels remain a potential risk factor.

Cash Flow

Cash flow analysis reveals challenges in generating free cash flow, with a negative Free Cash Flow in 2025. The Free Cash Flow Growth Rate is negative, reflecting constraints in cash generation. The Operating Cash Flow to Net Income Ratio deteriorated due to reduced cash inflows from operations, highlighting potential liquidity concerns. However, the Free Cash Flow to Net Income Ratio improved, suggesting better alignment of cash flow with profitability despite the negative free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.24B	29.11B	28.84B	26.91B	24.96B	23.80B
Gross Profit	2.00B	1.79B	2.10B	754.80M	1.06B	600.31M
EBITDA	1.26B	1.37B	1.53B	617.62M	569.32M	-475.15M
Net Income	2.20B	2.05B	213.91M	-400.58M	-650.04M	-2.23B
Balance Sheet
Total Assets	30.22B	31.06B	31.12B	30.07B	30.57B	29.75B
Cash, Cash Equivalents and Short-Term Investments	10.13B	11.62B	10.96B	9.55B	12.05B	10.87B
Total Debt	11.82B	12.62B	13.49B	13.51B	13.26B	12.15B
Total Liabilities	15.86B	16.82B	18.76B	17.81B	17.69B	16.08B
Stockholders Equity	14.36B	14.24B	12.37B	12.26B	12.89B	13.67B
Cash Flow
Free Cash Flow	0.00	-794.54M	1.09B	-2.46B	476.90M	-2.52B
Operating Cash Flow	0.00	254.63M	1.99B	7.28M	1.72B	-857.32M
Investing Cash Flow	0.00	1.74B	-708.82M	-2.59B	-1.51B	-1.27B
Financing Cash Flow	0.00	-1.10B	-255.61M	-20.18M	917.86M	2.27B

Uchiyama Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 341.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6059, the sentiment is Positive. The current price of 341 is above the 20-day moving average (MA) of 336.60, above the 50-day MA of 327.98, and above the 200-day MA of 309.13, indicating a bullish trend. The MACD of 4.95 indicates Positive momentum. The RSI at 60.17 is Neutral, neither overbought nor oversold. The STOCH value of 59.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6059.

Uchiyama Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2425	79 Outperform	¥3.10B	9.65	―	2.44%	-0.34%	-21.06%
7091	75 Outperform	¥4.39B	10.71	―	―	15.78%	120.80%
6059	68 Neutral	¥6.59B	3.00	―	2.93%	0.92%	1344.43%
7129	68 Neutral	¥3.08B	10.57	―	2.72%	4.76%	134.83%
2373	67 Neutral	¥7.86B	13.03	―	2.91%	7.60%	―
6557	65 Neutral	¥9.10B	25.65	―	―	11.69%	-38.92%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%